S3V Vascular Technologies Limited

1Introduction S3V Vascular Technologies Limited — founded in 2011, headquartered in Mysore, Karnataka. Focuses on development and manufacturing of advanced medical devices for cardiovascular and critical-care applications. S3V became the first company in the world to receive a manufacturing license for an expandable titanium-based Intervertebral Body Fusion Device / Expandable Spinal Cage — the first successful spinal implant was done in Pune, and S3V remains the only manufacturer of this expandable cage globally.

2Business Model S3V follows a fully integrated model combining in-house R&D, proprietary technology development, and regulated manufacturing facilities. It serves both Indian and global markets through: Direct hospital partnerships Clinician collaborations Medical-device distributors This ensures cost-effective, high-quality medical devices reach the market.

3Product Portfolio i) Drug-Eluting Stents (DES) and Bare-Metal Stents ii) PTCA and Neurovascular Catheters iii) Esophageal and Biliary Stents iv) India's first indigenous Mechanical Thrombectomy Device (for treating brain strokes) Goal: Reduce India's import reliance in the medical-device segment while improving affordability and clinical access.

4Industry & Market Opportunity Cardiovascular and neurovascular diseases are rising rapidly — India represents a massive demand base for minimally invasive medical devices. The neuro-intervention market alone is a $2-billion segment, currently dominated by imported products. S3V targets this gap through indigenous manufacturing, regulatory compliance (ISO-13485, CE approvals), and reduction of import costs — increasing access in India and emerging markets.

5Promoter Background Mr. Badari Narayan — over 30 years of industry experience, holds an M. Pharmacy degree and PGPMAX from ISB. Worked under Dr. A.P.J. Abdul Kalam in developing India's lowest-cost cardiac stents. Career milestones include: 316LVM stents (1999), Cobalt-Chromium stents (2004), Paclitaxel DES (2005), Sirolimus DES (2006), and PTCA catheters. Dr. Vijaya Gopal (MBBS) — heads the R&D division Vishnu Shreyas N.G. (qualified engineer) — heads Operations Both are Badari Narayan's sons, and this second generation has already been active in the business for the last five years.

6Strategic Capital Raise (2024) Raised ₹110 crore in March 2024 Pre-money valuation: ₹228 crore Post-money valuation: ₹338 crore Share price: ₹176 per share Capital allocated toward: debt reduction, working capital needs, manufacturing facility expansion Key investors: A.M. Naik, L&T Group executives (₹35+ crore), Madhusudan Kela & team (₹25+ crore), Utpal Sheth (Rare Enterprises), Sumit Jalan (Credit Suisse)

7Government-Backed Expansion Initiative (2025) Received support from the Technology Development Board (DST) to build India's first indigenous mechanical thrombectomy device for stroke treatment A dedicated 12-acre Neuro Division facility is being set up at Tamil Nadu Medical Devices Park Timeline: Prototype ready; commercial production begins December 2025 Sales expected from Q4 FY26 Full market impact visible by FY27

8Growth Strategy i) Scaling exports with global regulatory approvals (CE, US FDA) ii) Expanding neurovascular manufacturing capacity iii) Increasing clinical adoption leveraging domestic cost advantages iv) Strengthening innovation through collaboration with hospitals & clinicians.